Viyash Scientific Limited, formerly known as SeQuent Scientific Limited, announced its unaudited standalone and consolidated financial results for the quarter and nine months ended December 31, 2025, during its Board Meeting held on February 5, 2026. The company reported a consolidated revenue of ₹8,584 million for the third quarter, representing an 11% increase compared to ₹7,735 million in the corresponding quarter of the previous year. Profit after tax (PAT) reached ₹491 million, a substantial 16.9% growth from the ₹420 million reported in Q3 FY25. On a quarter-on-quarter basis, revenue showed a marginal increase of 1% from ₹8,500 million in Q2 FY26, while profit experienced a significant decrease of 32.7% from ₹730 million in the preceding quarter.

Viyash Scientific Limited is a leading integrated pharmaceutical enterprise with a specialized focus on the global animal health market and active pharmaceutical ingredients (APIs). Following the successful ₹8,000 crore merger with Viyash Life Sciences in late 2025, the company has emerged as India’s largest animal health player, operating 16 manufacturing facilities with 10 USFDA-approved units. The company offers a diverse portfolio including finished dose formulations, intermediates, and analytical services across 150+ countries. A major shareholder and key investor in the company is The Carlyle Group, which holds a significant stake through its affiliates CA Harbor Investments and CA Hull Investments. Recent updates in 2025 and early 2026 include the formal name change from SeQuent Scientific, the introduction of a new Employee Stock Option Scheme (VSL ESOP 2026), and a record order book exceeding ₹47 billion in the first nine months of FY26.